ArriVent BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	62.1	45.54	74.29	150.39	163.37
Short-Term Investments	264.28	267.28	144.57	-	-
Cash & Short-Term Investments	326.38	312.82	218.86	150.39	163.37
Cash Growth	85.36%	42.93%	45.53%	-7.95%	-
Other Current Assets	22.32	20.08	8.12	9.58	19.25
Total Current Assets	348.7	332.9	226.98	159.97	182.62
Net Property, Plant & Equipment	0.37	0.01	0.15	0.29	0.14
Long-Term Investments	-	-	47.68	-	-
Other Long-Term Assets	0.23	0.26	0.13	2.84	0.07
Total Assets	349.3	333.17	274.94	163.1	182.83
Accounts Payable	8.73	5.93	3.78	4.53	3.09
Accrued Expenses	16.17	20	13.33	6.95	5.14
Current Portion of Leases	0.1	0.01	0.16	0.14	0.13
Total Current Liabilities	25	25.95	17.27	11.62	8.36
Long-Term Leases	0.32	-	0.01	0.18	0.01
Total Long-Term Liabilities	0.32	-	0.01	0.18	0.01
Total Liabilities	25.32	25.95	17.29	11.8	8.37
Common Stock	-	0	0	-	-
Additional Paid-in Capital	772.21	711.85	496.2	4.65	3.4
Accumulated Other Comprehensive Income	-0.27	0.01	-0.21	-	-
Retained Earnings	-	-404.64	-238.33	-157.85	-88.51
Total Common Shareholders' Equity	323.98	307.22	257.65	-153.19	-85.11
Minority Interest	-	-	-	304.49	149.87
Shareholders' Equity	323.98	307.22	257.65	151.3	64.76
Total Liabilities & Equity	349.3	333.17	274.94	163.1	182.83
Total Debt	0.42	0.01	0.18	0.32	0.14
Net Cash (Debt)	325.96	312.81	218.69	150.07	163.23
Net Cash Growth	4.21%	43.04%	45.72%	-8.06%	-
Net Cash Per Share	7.91	8.13	6.95	70.10	127.82
Book Value	323.98	307.22	257.65	-153.19	-85.11
Book Value Per Share	7.86	7.99	8.19	-71.55	-66.64
Tangible Book Value	323.98	307.22	257.65	-153.19	-85.11
Tangible Book Value Per Share	7.86	7.99	8.19	-71.55	-66.64

SEC Filings: 10-K · 10-Q